Guardant Health (NASDAQ:GH) delivered an exceptional Q3 2025, significantly outperforming expectations with 39% year-over-year revenue growth, driven by the rapidly commercialized Shield screening test and accelerating oncology volumes, marking a pivotal shift towards long-term profitability for its core business.
Guardant Health (GH) has once again demonstrated its robust growth trajectory, reporting impressive third-quarter 2025 earnings that signal strong operational execution and a clear path toward its long-term financial targets. For the quarter ended September 2025, the company announced total revenue of $265.2 million, marking a substantial 39% increase over the same period last year. This performance not only exceeded market expectations but also positioned the core business for a crucial milestone: achieving cash flow positivity ahead of schedule.
The reported revenue represents a significant surprise, surpassing the Zacks consensus estimate of $234.58 million by 13.05%. Earnings per share (EPS) came in at -$0.39, an improvement from -$0.45 in the prior-year quarter, also beating the consensus estimate of -$0.48 by 18.75%, as reported by Zacks Equity Research. These figures underscore the effectiveness of Guardant Health’s strategic initiatives across its oncology, biopharma and data, and critically, its Shield screening segments.
Shield’s Breakthrough: Rapid Adoption and Financial Discipline
The star performer of the quarter was undeniably the Shield colorectal cancer (CRC) screening test. Generating $24.1 million in revenue from approximately 24,000 tests, Shield is now tracking at an impressive $100 million annualized run rate just one year into its commercial launch. This rapid adoption highlights its potential to transform early cancer detection, particularly by removing barriers to screening and integrating seamlessly into primary care practices.
Michael Bell, Chief Financial Officer, emphasized the significant improvement in Shield’s non-GAAP gross margin, which soared to 55%, up from negative levels at its launch. This improvement is attributed to strong average selling prices (ASPs) under the Medicare ADLT rate of $1,495 and a disciplined focus on reimbursable tests, keeping the cost per test below $500. During the earnings call, Bell addressed analyst inquiries about Shield ASP dynamics, confirming the stability of the $1,495 ADLT rate and expecting continued strength from Medicare Advantage payers. He noted that the primary fluctuation in ASP over the next few years will depend on the increasing proportion of commercial patients and the time it takes to establish their reimbursement rates, as detailed in the Motley Fool Transcribing of the call.
Strategic partnerships are further accelerating Shield’s reach. Collaborations with Quest Diagnostics and PATH Group are set to expand Shield access nationwide, leveraging Quest’s extensive connectivity to 650,000 clinician and hospital accounts, 2,000 patient service centers, and 6,000 in-office phlebotomists. These partnerships, expected to become fully operational in 2026, will significantly strengthen Guardant Health’s competitive position in the primary care market by enhancing ordering experiences and accelerating awareness and adoption.
Beyond CRC, Shield Multi-Cancer Detection (MCD) is now available nationwide through a clinical data collection initiative. This initiative, designed to reach hundreds of thousands of participants, aims to generate large-scale prospective evidence on MCD’s performance, clinical value, and safety profile, thereby building a substantial “data moat” for future innovation and regulatory submissions.
Oncology Business: The Enduring Power of a Platform Approach
While Shield commands attention, Guardant Health’s foundational oncology business continues its impressive acceleration. Oncology revenue grew 31% to $184.4 million, driven by a 40% year-over-year increase in oncology test volumes, totaling approximately 74,000 tests. This strong performance stems from the continued momentum of Guardant360 Liquid, Guardant360 Tissue, and Reveal.
Guardant360 Liquid achieved its fifth consecutive quarter of accelerating growth, with volumes up more than 30% year-over-year. Co-Chief Executive Officer Helmy Eltoukhy highlighted that Guardant360 is not just a test but an “application platform,” with the introduction of “smart apps” and Infinity AI continuously expanding its clinical utility and capabilities. This approach allows for a multiplication of clinical insights, guiding physicians at every step of the patient journey and differentiating Guardant Health in the liquid comprehensive genomic profiling (CGP) market.
Reveal, the company’s minimal residual disease (MRD) test, remains its fastest-growing oncology product, benefiting from Medicare coverage for CRC surveillance and ongoing strength in breast and lung cancer indications. Guardant Health is aggressively pursuing expanded reimbursement for Reveal, with data submissions for immuno-oncology therapy monitoring and chemotherapy monitoring underway. The company is also developing an “ultra-sensitive tissue-informed MRD assay,” Reveal Ultra, to complement its existing tissue-free Reveal test, aiming to set new benchmarks in sensitivity.
Regulatory momentum is also strong, with the submission of a Premarket Approval (PMA) application to the FDA for Guardant360 Liquid. This aims to simplify the portfolio with a single flagship FDA-approved liquid biopsy for therapy selection, which could also pave the way for Advanced Diagnostic Laboratory Test (ADLT) designation, ensuring appropriate reimbursement for its expanded offerings.
Financial Health and Future Trajectory
Guardant Health’s overall financial health showed significant improvement. The non-GAAP gross margin increased to 66% in Q3 2025, up from 63% in the prior-year period, primarily due to a substantial reduction in Reveal’s Cost of Goods Sold (COGS) to less than $500 per test and strong progress in Shield’s gross margin. While non-GAAP operating expenses increased by 22% to $228.8 million, this was primarily due to strategic investments in expanding the commercial infrastructure for Shield, reflecting a commitment to maximizing its first-mover advantage.
Adjusted EBITDA loss improved to $45.5 million, an improvement of $10.7 million year-over-year. Crucially, excluding the screening business, Guardant Health’s core operations became cash flow positive one quarter earlier than targeted, demonstrating strong underlying business fundamentals. The company ended the quarter with approximately $690 million in cash, cash equivalents, and restricted cash.
Based on this robust performance, Guardant Health has raised its full-year 2025 guidance for the third time this year:
- Total Revenue: Increased to $965 million–$970 million (approximately 31% growth).
- Oncology Revenue Growth: Raised to approximately 25% (previously 20%).
- Total Oncology Test Volume Growth: Forecasted to be more than 30% (previously more than 27%).
- Shield Revenue: Increased to $71 million–$73 million (previously $55 million–$60 million).
- Non-GAAP Gross Margin: Updated to 64%-65% (previously 63%-64%).
- Free Cash Flow Burn: Maintained at $225 million–$235 million, a significant improvement from $275 million in 2024.
The company remains committed to achieving company-wide cash flow breakeven by 2027, driven by continued oncology volume growth and strong Shield adoption.
Investment Implications: Long-Term Growth Catalysts
For investors, Guardant Health’s Q3 2025 earnings highlight several long-term growth catalysts. The company’s “platform” approach to its liquid biopsy technology, particularly Guardant360, ensures continuous expansion of clinical utility and market share gains. As Helmy Eltoukhy explained, the market is still in the “very early innings” for liquid biopsy, with potential to move from one test per lifetime to multiple tests per patient per year, driving a significant market expansion.
The aggressive commercialization of Shield positions Guardant Health to capture a first-mover advantage in the colossal colorectal cancer screening market. Partnerships with major players like Quest Diagnostics are not merely incremental but represent strategic accelerants to nationwide access and EMR integration, critical for scaling a diagnostic test. Furthermore, the extensive data generated from over 1 million cumulative clinical patient samples, including 350,000+ epigenetic profiles, forms a powerful “data moat” that fuels continuous product improvement and competitive differentiation.
The dual strategy in the MRD space with both tissue-free Reveal and the upcoming tumor-informed Reveal Ultra positions Guardant Health to address diverse clinical needs and capture a significant share of this rapidly evolving market. With improving gross margins and a clear roadmap to cash flow breakeven, Guardant Health is demonstrating that its innovative pipeline and commercial execution are translating into tangible financial results, setting a strong foundation for sustained growth in the years to come.
